1-5 of 5
Ludo M. Evers
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Clinical Trials & Observations
Lina van der Straten, Claudia A. M. Stege, Sabina Kersting, Kazem Nasserinejad, Julie Dubois, Johan A. Dobber, Clemens H. M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Ludo M. Evers, Fransien de Boer, Harry R. Koene, John Schreurs, Marjolein van der Klift, Gerjo A. Velders, Ellen van der Spek, Hanneke M. van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F. M. Posthuma, Hein P. J. Visser, Ilse Houtenbos, Cecile A. M. Idink, Djamila E. Issa, Ellen C. Dompeling, Henk C. T. van Zaanen, J. Hendrik Veelken, Henriette Levenga, Lidwine W. Tick, Wim E. Terpstra, Sanne H. Tonino, Peter E. Westerweel, Anton W. Langerak, Arnon P. Kater, Mark-David Levin
Journal: Blood
Blood (2023) 142 (13): 1131–1142.
https://doi.org/10.1182/blood.2023020195
Published: 2023
Includes: Supplemental data
Journal Articles

Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

Mark-David Levin, Sabina Kersting, Julie M.N. Dubois, Yvette Norden, Johan A Dobber, Yvonne W.S. Jauw, Anne-Marie van der Kevie-Kersemaekers, Clemens Mellink, Koen de Heer, Leonie van der Burg, Doreen Te Raa, Fransien de Boer, Jolanda Droogendijk, Cecile Idink, Marten R. Nijziel, Lidwine W. Tick, Inge Ludwig, Matthijs Silbermann, Aart Beeker, Mar Bellido, Ludo M. Evers, Gerben JC Zwezerijnen, Carsten U Niemann, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 4137–4139.
https://doi.org/10.1182/blood-2022-163209
Published: 2022
Journal Articles

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Fie Juhl Vojdeman, MD, Lone Bredo Pedersen, Doreen Te Raa, MD PhD, Vesa Juvonen, PhD, Yvette Norden, Geir Erland Tjønnfjord, MD DMsc, Eva Kimby, Maija Itälä-Remes, MD PhD, Anton W Langerak, Ludo M. Evers, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD PhD, Christian H. Geisler, MD PhD, Arnon P. Kater, MD, Carsten Utoft Niemann, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4312.
https://doi.org/10.1182/blood.V130.Suppl_1.4312.4312
Published: 2017
Journal Articles

Glycocalyx Perturbation in Patients with Sickle Cell Disease: Association with Disease Morbidity.

Eduard J. Beers van, MD, Pearl Landburg, MD, Max Nieuwdorp, MD, Ashley L. Duits, MS, PhD, Hans Vink, MS, PhD, Ludo M. Evers, MS, PhD, Bart J. Biemond, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 1204.
https://doi.org/10.1182/blood.V108.11.1204.1204
Published: 2006
Journal Articles

Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma

Patrick W. B. Derksen, Robert M. J. Keehnen, Ludo M. Evers, Marinus H. J. van Oers, Marcel Spaargaren, Steven T. Pals
Journal: Blood
Blood (2002) 99 (4): 1405–1410.
https://doi.org/10.1182/blood.V99.4.1405
Published: 2002